Evidence map›Paper›PMID 41170411›Full record

ArticleAnimal cells and systems2025

Novel TLR2 agonist Amuc_C derived from

Liang Chi, Chiao-Hsu Ke, Hsin-Yi Wu, I-Li Liu, Chih-Hung Huang, Chen-Si Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Animal cells and systems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Unveiling the Molecular Repertoire ofJournal of microbiology and biotechnology · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liang ChiDepartment of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Chiao-Hsu KeDepartment of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Hsin-Yi WuInstrumentation Center, National Taiwan University, Taipei, Taiwan.
I-Li LiuInstitute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Chih-Hung HuangDepartment of Chemical Engineering and Biotechnology, Institute of Chemical Engineering, National Taipei University of Technology, Taipei, Taiwan.
Chen-Si LinDepartment of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a challenging disease. Recent studies have gradually emphasized the development of novel immunotherapies rather than traditional treatments. Toll-like receptor (TLR) agonists are critical in innate immune responses to orchestrate anti-tumor efficacies, which are attributed to their aptitude to stimulate antigen-presenting cells (APCs) and thus activate tumor-specific T cells. Although several TLR agonists have been proposed for treating tumors, their therapeutic efficacy remains controversial. Therefore, the current study aimed to develop a novel TLR2 agonist, Amuc_1100 C-terminal (Amuc_C), a purified membrane protein from

Indexed as

Akkermansia muciniphilaAmuc_1100 C-terminalimmunomodulatory agentsToll-like receptor 2 agonisttranslational medicine

Identifiers

PMID41170411
PMCPMC12570232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.